Suppr超能文献

β受体阻滞剂治疗扩张型心肌病时的心肌基因表达

Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.

作者信息

Lowes Brian D, Gilbert Edward M, Abraham William T, Minobe Wayne A, Larrabee Patti, Ferguson Debra, Wolfel Eugene E, Lindenfeld JoAnn, Tsvetkova Tatiana, Robertson Alastair D, Quaife Robert A, Bristow Michael R

机构信息

Division of Cardiology and the Cardiovascular Institute, University of Colorado Health Sciences Center, Denver 80262, USA.

出版信息

N Engl J Med. 2002 May 2;346(18):1357-65. doi: 10.1056/NEJMoa012630.

Abstract

BACKGROUND

Beta-blocker therapy may improve cardiac function in patients with idiopathic dilated cardiomyopathy. We tested the hypothesis that beta-blocker therapy produces favorable functional effects in dilated cardiomyopathy by altering the expression of myocardial genes that regulate contractility and pathologic hypertrophy.

METHODS

We randomly assigned 53 patients with idiopathic dilated cardiomyopathy to treatment with a beta-adrenergic-receptor blocking agent (metoprolol or carvedilol) or placebo. The amount of messenger RNA (mRNA) for contractility-regulating genes (those encoding beta1- and beta2-adrenergic receptors, calcium ATPase in the sarcoplasmic reticulum, and alpha- and beta-myosin heavy-chain isoforms) and of genes associated with pathologic hypertrophy (beta-myosin heavy chain and atrial natriuretic peptide) was measured with a quantitative reverse-transcription polymerase chain reaction in total RNA extracted from biopsy specimens of the right ventricular septal endomyocardium. Myocardial levels of beta-adrenergic receptors were also measured. Measurements were conducted at base line and after six months of treatment, and changes in gene expression were compared with changes in the left ventricular ejection fraction as measured by radionuclide ventriculography.

RESULTS

Twenty-six of 32 beta-blocker-treated patients (those with complete mRNA measurements) had an improvement in left ventricular ejection fraction of at least 5 ejection-fraction (EF) units (mean [+/-SE] increase, 18.8+/-1.8). As compared with the six beta-blocker-treated patients who did not have a response (mean change, a decrease of 2.5+/-1.8 EF units), those who did have a response had an increase in sarcoplasmic-reticulum calcium ATPase mRNA and alpha-myosin heavy chain mRNA and a decrease in beta-myosin heavy chain mRNA. The change in sarcoplasmic-reticulum calcium ATPase was not present in the patients in the placebo group who had a spontaneous response. There were no differences between those who had a response and those who did not in terms of the change in mRNA or protein expression of beta-adrenergic receptors.

CONCLUSIONS

In idiopathic dilated cardiomyopathy, functional improvement related to treatment with beta-blockers is associated with changes in myocardial gene expression.

摘要

背景

β受体阻滞剂治疗可能改善特发性扩张型心肌病患者的心脏功能。我们检验了这样一个假设,即β受体阻滞剂治疗通过改变调节心肌收缩力和病理性肥大的心肌基因表达,从而在扩张型心肌病中产生有益的功能效应。

方法

我们将53例特发性扩张型心肌病患者随机分为β肾上腺素能受体阻滞剂(美托洛尔或卡维地洛)治疗组或安慰剂治疗组。采用定量逆转录聚合酶链反应,测定从右心室间隔心内膜活检标本中提取的总RNA中,调节收缩力的基因(编码β1和β2肾上腺素能受体、肌浆网钙ATP酶以及α和β肌球蛋白重链异构体的基因)和与病理性肥大相关的基因(β肌球蛋白重链和心钠素)的信使RNA(mRNA)量。同时测定心肌β肾上腺素能受体水平。在基线期和治疗6个月后进行测量,并将基因表达的变化与放射性核素心室造影测量的左心室射血分数的变化进行比较。

结果

32例接受β受体阻滞剂治疗的患者(有完整mRNA测量数据者)中有26例左心室射血分数至少提高了5个射血分数(EF)单位(平均[±标准误]增加18.8±1.8)。与6例无反应的β受体阻滞剂治疗患者(平均变化为射血分数降低2.5±1.8单位)相比,有反应的患者肌浆网钙ATP酶mRNA和α肌球蛋白重链mRNA增加,β肌球蛋白重链mRNA减少。安慰剂组有自发反应的患者未出现肌浆网钙ATP酶的变化。有反应者和无反应者在β肾上腺素能受体的mRNA或蛋白表达变化方面无差异。

结论

在特发性扩张型心肌病中,与β受体阻滞剂治疗相关的功能改善与心肌基因表达的变化有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验